THE MOBILE INSULIN TITRATION INTERVENTION PROGRAM TO TRANSITION FROM BASAL INSULIN TO A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (MITI-GLP1): USING DAILY SMS TEXT MESSAGES AND WEEKLY PHONE CALLS TO TRANSITION PRIMARY CARE PATIENTS WITH WELL-CONTROLLED TYPE 2 DIABETES FROM BASAL INSULIN TO A GLP1-RA

被引：0
|
作者：
Levy, Natalie K. [1 ]
Nerlino, Katie [1 ]
Bongalos, Sherlane B. [2 ]
Dasilva, Alexis [2 ]
Uzor, Chinye N. [2 ]
Sonubi, Olubunmi O. [2 ]
机构：
[1] NYU, Bellevue Hosp, Med, Sch Med, New York, NY USA
[2] Bellevue Hosp Ctr, Med, New York, NY USA
来源：
JOURNAL OF GENERAL INTERNAL MEDICINE | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：S637 / S637
页数：1
相关论文
共 46 条
  • [31] Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)
    Pozzilli, Paolo
    Norwood, Paul
    Jodar, Esteban
    Davies, Melanie J.
    Ivanyi, Tibor
    Jiang, Honghua
    Woodward, D. Bradley
    Milicevic, Zvonko
    DIABETES OBESITY & METABOLISM, 2017, 19 (07): : 1024 - 1031
  • [32] Effectiveness of adding glucagon-like peptide-1 receptor agonist on diabetes complications and mortality among basal insulin-treated people with type 2 diabetes: A real-world Korean study
    Ha, Kyoung Hwa
    Kim, Won
    Kim, Dong Han
    Kim, Dae Jung
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2025, 39 (05)
  • [33] Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study
    Bailey, Timothy S.
    Gill, Jasvinder
    Jones, Merwyn S.
    Shenoy, Laxmi
    Nicholls, Charlie
    Westerbacka, Jukka
    DIABETES OBESITY & METABOLISM, 2022, 24 (08): : 1617 - 1622
  • [34] Glycaemic target attainment with lixisenatide, a new, once-daily glucagon-like peptide 1 (GLP-1) receptor agonist, as add-on to oral hypoglycaemic agents or basal insulin in Type 2 diabetes: a regression analysis of pooled phase three clinical trial data
    Davies, M. J.
    Khunti, K.
    Lin, J.
    DIABETIC MEDICINE, 2013, 30 : E7 - E7
  • [35] Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor use: A post hoc analysis of ONWARDS 1-5
    Vilsboll, Tina
    Fu, Ariel
    Kellerer, Monika
    Kumar, Bharath
    Sogaard, Stinne Byrholdt
    Goldenberg, Ronald
    DIABETES OBESITY & METABOLISM, 2025,
  • [36] Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes
    Mari, A.
    Del Prato, S.
    Ludvik, B.
    Milicevic, Z.
    de la Pena, A.
    Shurzinske, L.
    Karanikas, C. A.
    Pechtner, V.
    DIABETES OBESITY & METABOLISM, 2016, 18 (08): : 834 - 839
  • [37] Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis
    Weng, Junling
    Tao, Ying
    Xu, Zian
    Zhou, Shanyan
    Xiao, Dunming
    Zhu, Zhixu
    Zheng, Ruizhi
    Yang, Yi
    Chen, Yingyao
    JOURNAL OF EVIDENCE BASED MEDICINE, 2024, 17 (02) : 370 - 376
  • [38] Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies
    Liu, Fuqiang
    Liu, Yuan
    Liu, Minzhi
    Wu, Guangyu
    Zhang, Minlu
    Zhang, Xia
    Cui, Nan
    Yin, Huiqiu
    Chen, Li
    JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (08) : 1386 - 1394
  • [39] Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518
    Rosenstock, Julio
    DIABETES CARE, 2021, 44 (11) : E196 - E197
  • [40] INTENSIFICATION WITH INSULIN GLARGINE 300 U/ML (Gla-300) OR FIRST- GENERATION BASAL INSULINS (BIs) IN PEOPLE WITH TYPE 2 DIABETES (T2D) ON ONCE-WEEKLY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAs): DELIVER NEW-G
    Umpierrez, G.
    Bailey, T.
    Mahieu, A.
    Li, X.
    Mabunay, M. A.
    Fonseca, V
    VALUE IN HEALTH, 2024, 27 (06) : S83 - S83
12345